The antioncogenic effect of Beclin-1 and FOXP3 is associated with SKP2 expression in gastric adenocarcinoma: Erratum.

In the article, “The antioncogenic effect of Beclin-1 and FOXP3 is associated with SKP2 expression in gastric adenocarcinoma”,[ which appears in Volume 100, Issue 33 of Medicine, Figure 2B was incorrect and has been corrected. The accurate figure is below:

Figure 2

Analysis of the overall survival and disease-free survival rates based on SKP2 expression in gastric adenocarcinoma. A. The patients with a positive SKP2 expression showed a significantly higher cumulative survival rate than patients with a negative SKP2 expression in gastric adenocarcinoma (P = .007). B The patients with a positive SKP2 expression showed a significantly higher disease-free survival rate than the patients with a negative SKP2 expression (P < .0001) C. The patients with a positive SKP2 expression presented a significantly higher disease-free survial rate than the patients with a negative SKP2 expression among the tumoral FOXP3 population (P <.001). D. Difference in disease-free survival between positive SKP2 expression and negative SKP2 expression is attenuated among tumoral FOXP3 population (P = .419). FOXP3 = forkhead box protein P3, SKP2 = S-phase kinase-associated protein 2.